Welcome to the international HTA database

Showing [23806 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2013	Haute Autorite de sante (HAS)	[Bone substitutes]
2013	National Institute for Health and Care Excellence (NICE)	Ambu aScope4 Broncho for use in unexpected difficult airways. NICE medical technologies guidance 14
2013	NIHR Health Technology Assessment programme	Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer. A systematic review and overview of reviews
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pediatric stretchers and stretcher cribs: safety and guidelines
2013	HAYES, Inc.	Yoga for chronic low back pain
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pain neurophysiology education for the management of persistent pain: clinical evidence and guidelines
2013	Haute Autorite de sante (HAS)	[Bypass prostheses]
2013	Malaysian Health Technology Assessment (MaHTAS)	QuantiFERON® -TB Gold
2013	Agency for Healthcare Research and Quality (AHRQ)	Assessment on implantable defibrillators and the evidence for primary prevention of sudden cardiac death
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	The use of restraints during acute mental health interventions: a review of the clinical evidence and guidelines
2013	HAYES, Inc.	Immunoglobulin gene testing in b-cell lymphoma
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Negative pressure wound therapy for the management of high risk surgical incisions or high risk patients: clinical effectiveness, cost-effectiveness, and guidelines
2013	Malaysian Health Technology Assessment (MaHTAS)	Platelet rich plasma for treatment of osteoarthritis
2013	NIHR Health Technology Assessment programme	HESTER study: Has electrical sinus translated into effective remodelling?
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Updated reports and recommendations on second- and third-line therapies for type 2 diabetes
2013	HAYES, Inc.	MammaPrint for prognosis of breast cancer recurrence
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Multi-dose contrast media for patients undergoing computed tomography: clinical benefits, harms, and guidelines
2013	National Institute for Health and Care Excellence (NICE)	Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract. NICE technology appraisal guidance 272
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Cefazolin for preoperative prophylaxis in overweight adults having any type of surgery: clinical effectiveness and guidelines
2013	HAYES, Inc.	Phenylalanine hydroxylase (PAH) deficiency (including phenylketonuria [PKU])
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Follow-up imaging for simple adnexal cysts: clinical evidence, cost-effectiveness and guidelines
2013	Haute Autorite de sante (HAS)	[Spinal implants (interbody cage, interspinous process spacer, spacer, lumbosacral support implant)]
2013	Malaysian Health Technology Assessment (MaHTAS)	Autologous peripheral blood stem cells for articular cartilage repair
2013	National Institute for Health and Care Excellence (NICE)	Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal). NICE technology appraisal guidance 273
2013	NIHR Health Technology Assessment programme	The clinical and cost-effectiveness of different treatment pathways for neuropathic pain (NP)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Indigenous knowledge for smoking cessation: benefits and effectiveness
2013	HAYES, Inc.	PLP1-related disorders (including pelizaeus-merzbacher disease [PMD])
2013	Penn Medicine Center for Evidence-based Practice (CEP)	Central venous catheter removal
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Ultrasound versus computed tomography for children with suspected appendicitis: clinical evidence, cost-effectiveness, and guidelines
2013	Malaysian Health Technology Assessment (MaHTAS)	NH2 Drug Lab (DRUGKOP)
2013	National Institute for Health and Care Excellence (NICE)	Ranibizumab for treating diabetic macular oedema. NICE technology appraisal guidance 274
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Screening and diagnostic tools for autism spectrum disorder in children: a review of guidelines
2013	HAYES, Inc.	Prolaris test for prediction of prostate cancer progression
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Delivery of podiatry care for adults with diabetes or chronic foot conditions: a review of the clinical effectiveness
2013	Malaysian Health Technology Assessment (MaHTAS)	Mobile phone with portable electrocardiogram (ECG) device
2013	National Institute for Health and Care Excellence (NICE)	Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation. NICE technology appraisal guidance 275
2013	NIHR Health Technology Assessment programme	Exercise for depression in care home residents: a randomised controlled trial with cost-effectiveness analysis (OPERA)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety
2013	HAYES, Inc.	Cold compression therapy for orthopedic conditions
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	X-ray series for foot and ankle injuries: clinical evidence, cost-effectiveness, and guidelines
2013	Malaysian Health Technology Assessment (MaHTAS)	INJEX (needle free drug delivery system)
2013	National Institute for Health and Care Excellence (NICE)	Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis. NICE technology appraisal guidance 276
2013	Institut national d'excellence en sante et en services sociaux (INESSS)	[Assessment of the PARLER (Programme d'Accès Rapide Lavallois en Rhumatologie) program]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Counselling or psychotherapy interventions for patients with a history of sexual or physical assault: patient benefits, harms, and guidelines
2013	HAYES, Inc.	Endoscopic epidural adhesiolysis for chronic back pain
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Adjuvant and neoadjuvant chemotherapy and radiation for the treatment of rectal cancer: economic evidence
2013	National Institute for Health and Care Excellence (NICE)	Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal). NICE technology appraisal guidance 277
2013	National Institute for Health and Care Excellence (NICE)	E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta. NICE medical technologies guidance 16
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Automation for the preparation of intravenous solutions for acute care patients: cost-effectiveness and safety
2013	HAYES, Inc.	Endovascular iliac atherectomy for treatment of peripheral arterial disease
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Optimal screening procedures prior to physician visits: guidelines
2013	National Institute for Health and Care Excellence (NICE)	Omalizumab for treating severe persistent allergic asthma. NICE technology appraisal guidance 278
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Sexual Assault Nurse Evaluation (SANE) rape crisis procedure: clinical effectiveness and guidelines
2013	HAYES, Inc.	Epidural injection of enbrel (etanercept; Immunex Corp.) for treatment of low back pain due to lumbar disc disease
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Anaphylaxis in seniors eeceiving intravenous antibiotics in long-term care: clinical evidence and guidelines
2013	Malaysian Health Technology Assessment (MaHTAS)	HAIFU® Model- Jc focused ultrasound tumor therapeutic system - an update
2013	National Institute for Health and Care Excellence (NICE)	Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures. NICE technology appraisal guidance 279
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Dornase alfa for patients with cystic fibrosis: a review of the clinical efficacy and cost-effectiveness
2013	HAYES, Inc.	Galectin-3 in vitro diagnostic assay (BG Medicine Inc.) for the management of patients with chronic heart failure
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Oral lidocaine for reflux or mucositis: clinical evidence and guidelines
2013	National Institute for Health and Care Excellence (NICE)	Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion. NICE technology appraisal guidance 283
2013	Institut national d'excellence en sante et en services sociaux (INESSS)	[The efficacy of rehabilitative interventions and pharmacological treatments for children aged 2 to 12 years with autism spectrum disorder (ASD)]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Total contact casts for diabetic foot ulcers: cost-effectiveness
2013	HAYES, Inc.	Home-based cervical traction for treatment of neck pain
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Prevention and management of violence in long-term care: clinical evidence and guidelines
2013	Malaysian Health Technology Assessment (MaHTAS)	EndostatTM antimicrobial treatment
2013	National Institute for Health and Care Excellence (NICE)	Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer. NICE technology appraisal guidance 284
2013	NIHR Health Technology Assessment programme	Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Point of care testing for human chorionic gonadotropin, creatinine, and blood urea nitrogen: cost-effectiveness
2013	HAYES, Inc.	Home ultraviolet B phototherapy for psoriasis
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	High-sensitivity cardiac troponin for the rapid diagnosis of acute coronary syndrome in the emergency department
2013	National Institute for Health and Care Excellence (NICE)	Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer. NICE technology appraisal guidance 285
2013	NIHR Health Technology Assessment programme	The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No. 150 and part review of technology appraisal No. 118): a systematic review and economic model
2013	Agency for Healthcare Research and Quality (AHRQ)	Testing of CYP2C19 variants and platelet reactivity for guiding antiplatelet treatment
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Tranexamic acid for the management of bleeding: a review of the clinical effectiveness and guidelines
2013	HAYES, Inc.	Musculoskeletal ultrasonography for diagnosis of low back pain
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Components and materials used for total hip replacement: a review of the comparative clinical effectiveness
2013	National Institute for Health and Care Excellence (NICE)	Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal). NICE technology appraisal guidance 286
2013	Agency for Healthcare Research and Quality (AHRQ)	Evaluation and treatment of tinnitus: comparative effectiveness
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Endovascular therapy for elective and ruptured abdominal aortic aneurysm procedures: a description of utilization trends across Canada
2013	HAYES, Inc.	Outpatient cervical traction for treatment of neck pain
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Knee implant systems: a review of the comparative clinical effectiveness
2013	National Institute for Health and Care Excellence (NICE)	Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism. NICE technology appraisal guidance 287
2013	Agency for Healthcare Research and Quality (AHRQ)	Interventions for adult offenders with serious mental illness
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Codeine and acetylsalicylic acid for the management of post-tonsillectomy or adenoidectomy pain: a review of the clinical evidence
2013	HAYES, Inc.	Percutaneous epidural adhesiolysis for chronic back pain
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Intramuscular oxytocin for the prevention of post-partum hemorrhage outside the hospital: clinical evidence and guidelines
2013	National Institute for Health and Care Excellence (NICE)	Dapagliflozin in combination therapy for treating type 2 diabetes. NICE technology appraisal guidance 288
2013	Agency for Healthcare Research and Quality (AHRQ)	Treatments for seasonal allergic rhinitis
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Antimicrobial ointments for patients undergoing hemodialysis: a review of evidence-based guidelines
2013	HAYES, Inc.	Postoperative intensity-modulated radiation therapy for sinus cancers
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Warming of amniofluid: safety
2013	National Institute for Health and Care Excellence (NICE)	Mirabegron for treating symptoms of overactive bladder. NICE technology appraisal guidance 290
2013	Institut national d'excellence en sante et en services sociaux (INESSS)	[Advisability of expanding the Québec newborn blood screening program]
2013	Agency for Healthcare Research and Quality (AHRQ)	Treatment of atrial fibrillation
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Single-use versus single patient-use electric breast pump kits for the prevention of hospital-acquired infections in mothers and newborns: comparative safety
2013	HAYES, Inc.	Postoperative intra-articular viscosupplementation for treatment of knee conditions
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Point of care testing compared to laboratory testing for the assessment of white blood cell counts and differentials: a review of the clinical effectiveness, diagnostic precision and accuracy, cost-effectiveness, and guidelines
2013	National Institute for Health and Care Excellence (NICE)	Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder. NICE technology appraisal guidance 292
2013	Agency for Healthcare Research and Quality (AHRQ)	Screening for Methicillin-Resistant Staphylococcus Aureus (MRSA)